Challenges of PK/PD measurements in modern drug development

被引：58

作者：

Workman, P ^{[1
]}

机构：

[1] Canc Res Inst, Canc Res UK, Ctr Canc Therapeut, Sutton SN2 5NG, Surrey, England

来源：

EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷 / 16期

关键词：

D O I：

10.1016/S0959-8049(02)00395-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：2189 / 2193

页数：5

共 27 条

[1]

Aboagye EO, 1996, ANTI-CANCER DRUG DES, V11, P231

[2] The relationship between tumour oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554 [J].

Aboagye, EO ;

Maxwell, RJ ;

Horsman, MR ;

Lewis, AD ;

Workman, P ;

Tracy, M ;

Griffiths, JR .

BRITISH JOURNAL OF CANCER, 1998, 77 (01) :65-70

[3]

Aboagye EO, 1997, CANCER RES, V57, P3314

[4]

Aboagye EO, 1998, ANTI-CANCER DRUG DES, V13, P703

[5]

BANERJI U, 2002, P AM ASSOC CANC RES, V43, P1352

[6]

Brizel DM, 1996, CANCER RES, V56, P941

[7]

Chung Yuen-Li, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P73

[8]

Chung Yuen-Li, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P336

[9] Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential [J].

Clarke, PA ;

Poele, RT ;

Wooster, R ;

Workman, P .

BIOCHEMICAL PHARMACOLOGY, 2001, 62 (10) :1311-1336

[10] Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of hsp90 molecular chaperone [J].

Clarke, PA ;

Hostein, I ;

Banerji, U ;

Di Stefano, F ;

Maloney, A ;

Walton, M ;

Judson, I ;

Workman, P .

ONCOGENE, 2000, 19 (36) :4125-4133

← 1 2 3 →